Class II-associated invariant chain peptide as predictive immune marker in minimal residual disease in acute myeloid leukemia.

ABSTRACT: The majority of patients with acute myeloid leukemia (AML) reach complete remission after high-dose chemotherapy. Still, half of these patients experience a relapse due to presence of minimal residual disease (MRD). Here we discuss the poor prognostic role of class II-associated invariant chain peptide (CLIP) expression on residual leukemic cells.

SUBMITTER: van Luijn MM 

PROVIDER: S-EPMC4353169 | biostudies-literature | 2014 Dec

REPOSITORIES: biostudies-literature